"Targeted Antibodies Boost Chemo Effectiveness in Tumor Cells"

Antibody drug conjugates (ADCs) are revolutionizing cancer treatment by delivering chemotherapy directly into tumor cells, increasing effectiveness and reducing side effects. Recent studies presented at the ASCO conference show promising results for patients with multiple myeloma and HER2-low breast cancer, extending the time without disease progression. ADCs, described as "smart warheads," are becoming a more precise and potent option in oncology, with ongoing research aimed at improving their stability and targeting capabilities.